Indaptus net loss narrows 66% to $1.8 million in Q2 FY26

PUBT · 1d ago
Indaptus net loss narrows 66% to $1.8 million in Q2 FY26
  • Indaptus posted a Q2 net loss of USD 1.8 million, narrowing from USD 5.2 million a year earlier; loss per share improved to USD 0.02.
  • R&D expense plunged 83% to USD 363,127, reflecting lower Decoy20 Phase 1 clinical costs plus payroll cuts after headcount reductions.
  • G&A expense fell 37% to USD 1.45 million on lower payroll-related costs plus changes in public-company costs during a management transition.
  • Completed a USD 12 million private placement at USD 0.6 per share; ended Q2 with USD 7.6 million cash plus USD 4 million short-term investments.
  • Halted Decoy20 enrollment with no participants remaining, leaving no active clinical programs; began a neurology and sleep research collaboration while weighing strategic alternatives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9808497) on August 13, 2026, and is solely responsible for the information contained therein.